Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8XYE

Crystal structure of SARS-CoV-2 BA.4 RBD and human ACE2

Summary for 8XYE
Entry DOI10.2210/pdb8xye/pdb
DescriptorProcessed angiotensin-converting enzyme 2, Spike protein S1, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
Functional Keywordssars-cov-2 ba.4, human ace2, viral protein/hydrolase, viral protein-hydrolase complex
Biological sourceHomo sapiens (human)
More
Total number of polymer chains4
Total formula weight186113.47
Authors
Lan, J.,Wang, C.H. (deposition date: 2024-01-19, release date: 2025-01-22, Last modification date: 2025-04-16)
Primary citationWang, C.,Zhang, Y.,Yang, C.,Ren, W.,Qiu, C.,Fan, S.,Ding, Q.,Lan, J.
Receptor binding mechanism and immune evasion capacity of SARS-CoV-2 BQ.1.1 lineage.
Virology, 600:110241-110241, 2024
Cited by
PubMed Abstract: The global spread of COVID-19 remains a significant threat to human health. The SARS-CoV-2 BQ.1.1 lineage, including BA.5.2, BF.7, BQ.1 and BQ.1.1, caused a new soaring of infection cases due to rapid transmission. However, the receptor binding mechanism and immune evasion capacity of these variants need to be explored further. Our study found that while the BA.5.2, BF.7 and BQ.1.1 variants pseudovirus had similar cell entry efficiency, the BF.7 and BQ.1.1 RBD bound to human ACE2 (hACE2) with a slightly stronger affinity than the BA.5.2 RBD. Structural analysis revealed R346T, K444T, and N460K mutations altered RBD-hACE2 binding interface details and surface electrostatic potential of BQ.1.1 RBD. Serum neutralization tests showed BQ.1.1 variant had stronger immune evasion capacity than BA.5.2 and BF.7 variants. Our findings illustrated the receptor binding mechanism and serological neutralization activity of the BA.5.2, BF.7 and BQ.1.1 variants, which verified the necessity for further antibody therapy optimization and vaccination development.
PubMed: 39270455
DOI: 10.1016/j.virol.2024.110241
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.32 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon